Abstract
Matrix metalloproteinases (MMPs) belong to a family of closely related calcium- and zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix (ECM) proteins that are associated with the tumorigenic processes. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful chemotherapeutic agents for the treatment of malignant cancer, osteoarthritis, and rheumatoid arthritis. A vast number of small molecular MMPIs have been developed in recent years. Although there have been considerable preclinical and clinical studies on these inhibitors, most of the effective candidates in clinical trials, however, have yielded unsatisfactory results, thus they are as yet unavailable for use as therapeutic drugs. Currently, more efforts have been directed to the design of specific inhibitors towards certain MMP family members for selective usage. This review will focus primarily on an analysis of recent developed MMPIs that have entered preclinical or clinical trials, and recently registered patents with regard to new highly selective MMPIs in USA or patent applications related to the specific inhibitors of MMPs. We also analyze the clinical failure and discuss the possible strategies to best optimize the development of these novel agents.
Keywords: Matrix metalloproteinases (MMPs), inhibitors, specific, selectivity
Recent Patents on Anti-Cancer Drug Discovery
Title: Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs)
Volume: 5 Issue: 2
Author(s): Xun Li and Ji-Feng Wu
Affiliation:
Keywords: Matrix metalloproteinases (MMPs), inhibitors, specific, selectivity
Abstract: Matrix metalloproteinases (MMPs) belong to a family of closely related calcium- and zinc-dependent endopeptidases involved in the degradation and remodeling of extracellular matrix (ECM) proteins that are associated with the tumorigenic processes. MMPs promote tumor invasion and metastasis, regulating host defense mechanisms and normal cell function. Thus, MMP inhibitors (MMPIs) are expected to be useful chemotherapeutic agents for the treatment of malignant cancer, osteoarthritis, and rheumatoid arthritis. A vast number of small molecular MMPIs have been developed in recent years. Although there have been considerable preclinical and clinical studies on these inhibitors, most of the effective candidates in clinical trials, however, have yielded unsatisfactory results, thus they are as yet unavailable for use as therapeutic drugs. Currently, more efforts have been directed to the design of specific inhibitors towards certain MMP family members for selective usage. This review will focus primarily on an analysis of recent developed MMPIs that have entered preclinical or clinical trials, and recently registered patents with regard to new highly selective MMPIs in USA or patent applications related to the specific inhibitors of MMPs. We also analyze the clinical failure and discuss the possible strategies to best optimize the development of these novel agents.
Export Options
About this article
Cite this article as:
Li Xun and Wu Ji-Feng, Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs), Recent Patents on Anti-Cancer Drug Discovery 2010; 5 (2) . https://dx.doi.org/10.2174/157489210790936234
DOI https://dx.doi.org/10.2174/157489210790936234 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Estrogen, Immunity & Autoimmune Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Protection by Natural Honey Against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Lipid Lowering Agents, Inflammation and Atherosclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders
Current Rheumatology Reviews Do Rheumatoid Arthritis Patients Rate their Health Status Different than their Caregivers?
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Emergence of Lipid-Based Vesicular Carriers as Nanoscale Pharmacotherapy in Rheumatoid Arthritis
Recent Patents on Nanomedicine The Dialogue Between Endothelial Cells and Monocytes/Macrophages in Vascular Syndromes
Current Pharmaceutical Design Clinical Pharmacokinetics of Ibuprofen Arginine
Current Clinical Pharmacology Immunotherapy with Peptides in Systemic Lupus Erythematosus
Current Medicinal Chemistry Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Human-Derived Organ-on-a-Chip for Personalized Drug Development
Current Pharmaceutical Design The Situation of Chemokine Ligands and Receptors Gene Expression, Following the Oral Administration of Drug Mannuronic Acid in Rheumatoid Arthritis Patients
Recent Patents on Inflammation & Allergy Drug Discovery Formulation Development and Characterization of Guar Gum Microspheres for Colon Delivery
Nanoscience & Nanotechnology-Asia Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Human Interleukin-19: Structure, Function and Disease Associations
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Biological Therapies For Inflammatory Bowel Disease: Research DrivesClinics
Mini-Reviews in Medicinal Chemistry